Lauren Moran

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase

Wei‐Sheng Huang, Shuangying Liu, Dong Zou et al. · Journal of Medicinal Chemistry · 2016 · 392 citations · Full text

Drug Target, Anaplastic Lymphoma Kinase, Tumor Biology +18

The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models

Sen Zhang, Rana Anjum, Rachel M. Squillace et al. · Clinical Cancer Research · 2016 · 321 citations · Full text

Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models

Joseph M. Gozgit, Matthew J. Wong, Lauren Moran et al. · Molecular Cancer Therapeutics · 2012 · 317 citations · Full text

Abstract LB-298: AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066 (PF1066)

Sen Zhang, Frank Wang, Jeffrey Keats et al. · Cancer Research · 2010 · 50 citations

Drug Target, Molecular Biology, Cancer Biology +25

Antitumor Activity of Ridaforolimus and Potential Cell-Cycle Determinants of Sensitivity in Sarcoma and Endometrial Cancer Models

Rachel M. Squillace, David F. Miller, Michelle Cookson et al. · Molecular Cancer Therapeutics · 2011 · 45 citations · Full text

Antitumor Activity, Gynecology, Pathology +16